Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Prostate Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm
Male Reproductive System Neoplasm
Prostate Neoplasm

Subtype

Prostate Neoplasm

CI-CAN-00003778Explore in graph →

Non-malignant1,453 active trials24 approved drugs58 evidence items

NCIt: C3343
MeSH: D011471

Overview
Statistics
Survival
Genomics28
Variants & evidence58
Drugs18
Trials6544
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (260)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 260 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
· JCO Precis Oncol · 2023 · PMID 36753688 · validated civic_curation pubmed
Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.
· Onco Targets Ther · 2015 · PMID 26261420 · validated civic_curation pubmed
A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.
· Front Pharmacol · 2014 · PMID 24782778 · validated civic_curation pubmed
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
· Cancer Discov · 2013 · PMID 23779130 · validated civic_curation pubmed
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
· Cancer Res · 2003 · PMID 12517791 · validated civic_curation pubmed
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
· Proc Natl Acad Sci U S A · 2001 · PMID 11504908 · validated civic_curation pubmed
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
· Cancer Res · 2009 · PMID 19244107 · validated

Showing 226–250 of 260 publications

← Previous
1
…
9
10
11
Next →

civic_curation

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

· Cancer Res · 2009 · PMID 19117982 · validated civic_curation pubmed

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.

· J Clin Invest · 2024 · PMID 38687617 · validated civic_curation pubmed

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

· Cancer Cell · 2015 · PMID 25670080 · validated civic_curation pubmed

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

· Clin Cancer Res · 2012 · PMID 22623731 · validated civic_curation pubmed

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

· Cancer Cell · 2015 · PMID 25544636 · validated civic_curation pubmed

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

· J Cell Biochem · 2016 · PMID 27153245 · validated civic_curation pubmed

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

· Autophagy · 2015 · PMID 26391455 · validated civic_curation pubmed

Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

· Int J Oncol · 2016 · PMID 26892177 · validated civic_curation pubmed

Beltran et al. Nat Med 2016

· 2016 · PMID 26855148 · validated cbioportal_study pubmed

Barbieri et al. Nat Genet 2012

· 2012 · PMID 22610119 · validated cbioportal_study pubmed

Baca et al. Cell 2013

· 2013 · PMID 23622249 · validated cbioportal_study pubmed

Nguyen et al. Eur Urol 2020

· 2020 · PMID 32317181 · validated cbioportal_study pubmed

Fraser et al. Nature 2017

· 2017 · PMID 28068672 · validated cbioportal_study pubmed

Shancheng et al. Eur Urol 2017

· 2017 · PMID 28927585 · validated cbioportal_study pubmed

Kumar et al. Nat Med 2016

· 2016 · PMID 26928463 · validated cbioportal_study pubmed

Stopsack et al. Clin Cancer Res 2020

· 2020 · PMID 32220891 · validated cbioportal_study pubmed

Grasso et al. Nature 2012

· 2012 · PMID 22722839 · validated cbioportal_study pubmed

Stopsack et al. Clin Cancer Res 2022

· 2022 · PMID 34667026 · validated cbioportal_study pubmed